Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonella Castagna

Showing results (1-10 of 554) with videos related to

Pageof 56
Sort By:
AIDS (London, England)|November 6, 2019
Two-drug regimens with dolutegravir for maintaining viral suppression: looking at the right companionAntonella Castagna,
The Lancet. Infectious Diseases|November 22, 2017
Stepping up HIV-1 low-level viraemia surveillance in South AfricaAntonella Castagna, Laura Galli
The Lancet. HIV|October 4, 2019
Switching antiretrovirals in older patientsNicola Gianotti, Antonella Castagna
Med (New York, N.Y.)|October 12, 2024
Twice-yearly lenacapavir: A milestone for HIV prevention in young African womenSilvia Nozza, Antonella Castagna
Expert Review of Anti-Infective Therapy|October 6, 2023
A four-drug combination oral tablet of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection in adultsCamilla Muccini, Antonella Castagna
Expert Opinion on Therapeutic Targets|May 2, 2024
HIV Pol: does it offer therapeutic targets for HIV?Camilla Muccini, Antonella Castagna
Plants (Basel, Switzerland)|March 13, 2024
The Multifaceted Responses of Plants to Visible and Ultraviolet RadiationMarco Santin, Antonella Castagna
Current Opinion in HIV and AIDS|May 11, 2018
BictegravirVincenzo Spagnuolo, Antonella Castagna, Adriano Lazzarin
Expert Opinion on Pharmacotherapy|June 19, 2018
Darunavir for the treatment of HIV infectionVincenzo Spagnuolo, Antonella Castagna, Adriano Lazzarin
Viruses|August 28, 2025
Safety, Tolerability, and Metabolic Effects of Long-Acting Cabotegravir and Rilpivirine in HIV Care: A Comprehensive ReviewMartina Bottanelli, Antonella Castagna, Camilla Muccini
Pageof 56

Showing results (1-10 of 554) with videos related to

Sort By:
Pageof 56
AIDS (London, England)|November 6, 2019
Two-drug regimens with dolutegravir for maintaining viral suppression: looking at the right companionAntonella Castagna,
The Lancet. Infectious Diseases|November 22, 2017
Stepping up HIV-1 low-level viraemia surveillance in South AfricaAntonella Castagna, Laura Galli
The Lancet. HIV|October 4, 2019
Switching antiretrovirals in older patientsNicola Gianotti, Antonella Castagna
Med (New York, N.Y.)|October 12, 2024
Twice-yearly lenacapavir: A milestone for HIV prevention in young African womenSilvia Nozza, Antonella Castagna
Expert Review of Anti-Infective Therapy|October 6, 2023
A four-drug combination oral tablet of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection in adultsCamilla Muccini, Antonella Castagna
Expert Opinion on Therapeutic Targets|May 2, 2024
HIV Pol: does it offer therapeutic targets for HIV?Camilla Muccini, Antonella Castagna
Plants (Basel, Switzerland)|March 13, 2024
The Multifaceted Responses of Plants to Visible and Ultraviolet RadiationMarco Santin, Antonella Castagna
Current Opinion in HIV and AIDS|May 11, 2018
BictegravirVincenzo Spagnuolo, Antonella Castagna, Adriano Lazzarin
Expert Opinion on Pharmacotherapy|June 19, 2018
Darunavir for the treatment of HIV infectionVincenzo Spagnuolo, Antonella Castagna, Adriano Lazzarin
Viruses|August 28, 2025
Safety, Tolerability, and Metabolic Effects of Long-Acting Cabotegravir and Rilpivirine in HIV Care: A Comprehensive ReviewMartina Bottanelli, Antonella Castagna, Camilla Muccini
Pageof 56